
NASDAQ:IDXX
This summary was created by AI, based on 2 opinions in the last 12 months.
IDEXX Laboratories (IDXX) has recently demonstrated impressive growth, with a topline growth acceleration to approximately 15%, a marked improvement from the mid-to-high single digits observed in previous quarters. Following the announcement of these solid numbers, the company's share price surged over 20% in a single day, reflecting strong investor confidence. Despite this positive momentum, current trading levels place IDXX at approximately 50 times Forward P/E, which raises concerns about its valuation given that future growth is projected at only 8%-9%. While investors are encouraged to hold their positions, there is a prevailing sentiment that it’s not an optimal time to add to investments in IDXX and that patience may yield better opportunities in the future.
IDEXX Laboratories is a American stock, trading under the symbol IDXX (previously IDXX-Q on Stockchase) on the NASDAQ (IDXX). It is usually referred to as NASDAQ:IDXX or IDXX
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on IDXX (previously IDXX-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY on WEAKNESS. Read the latest stock experts' ratings for IDEXX Laboratories.
IDEXX Laboratories was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for IDEXX Laboratories.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for IDEXX Laboratories.
IDEXX Laboratories is followed by 14 investors on Stockchase and is a trending stock that is worth watching.
On 2026-07-24, IDEXX Laboratories (IDXX) stock closed at a price of $546.42.
IDXX recently reported solid numbers as its topline growth accelerated to around 15% compared to previous quarters of around mid-to-high single digits. The company reacted favourably to the news as its share price jumped more than 20% in a single day. We think IDXX’s investment thesis as a high-quality, capital-light compounder in the pet healthcare industry remains intact. That being said, IDXX is now trading at around 50x Forward P/E, and growth over the next few years is expected to be around 8%-9%. We are comfortable holding the position here, but we don’t think it is too attractive to add at the current levels. We would prefer to be patient and wait for another opportunity to add to the name.
Unlock Premium - Try 5i Free